# The Role of Ischemia Modified Albumin in Patients With COVID-19

> **NCT05286268** · — · UNKNOWN · sponsor: **Larissa University Hospital** · enrollment: 194 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** Ischemia Modified Albumin

## Key facts

- **NCT ID:** NCT05286268
- **Lead sponsor:** Larissa University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-06
- **Primary completion:** 2022-07
- **Final completion:** 2022-07
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286268, "The Role of Ischemia Modified Albumin in Patients With COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05286268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*